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Abstract
Aims Heart failure (HF) is a multifactorial disease. Current treatments target only a fraction of the putative pathophysiolog-
ical pathways. In patients with HF, reduced cardiac output and congestion cause increased gut wall permeability. It has been
suggested that leakage of microbial products is detrimental to the heart, at least partly through activation of systemic inflam-
matory pathways, which again could promote gut leakage. Whether manipulating the gut microbiota can improve cardiac
function in patients with HF remains unknown. We aim to evaluate the effect of drugs targeting the gut microbiota on left
ventricular function, quality of life, and functional capacity, as well as on markers of gut leakage and inflammation, in stable
patients with HF with reduced ejection fraction.
Methods and results GutHeart is a randomized, open-label, controlled trial. Four centres will randomize 150 patients with
stable HF and a left ventricular ejection fraction <40% to receive the antibiotic rifaximin, the probiotic yeast Saccharomyces
boulardii (ATCC 74012), or no treatment (control) in a 1:1:1 fashion. Treatment will last for 3 months. The primary endpoint is
baseline-adjusted left ventricular ejection fraction as measured by echocardiography after 3 months. A further follow-up
6 months after randomization will be undertaken.
Conclusions This trial is likely to give new insights into important disease processes involving the gut microbiota in HF pa-
tients, hereby leading to new potential therapeutic strategies to prevent and down-regulate the inflammation seen in these
patients.
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Introduction
Heart failure (HF) is an important cause of morbidity and
mortality worldwide. The last decades have seen significant
progress in the treatment of HF,1 but the mortality and mor-
bidity remain high, suggesting that important pathogenic
mechanisms remain at least partly unmodified.2 Structural,
cellular, and molecular processes in the myocardium, referred
to as remodelling, characterize the development of HF. Left
ventricular (LV) remodelling enables the preservation of car-
diac output in the face of reduced myocardial contractility.
However, over time, this process turns maladaptive, leading
to a progressive decrease in LV function.3 Inflammatory and
metabolic mechanisms may play an important role in the
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development and progression of chronic HF, and these
interacting processes may contribute to the shift from adap-
tive to maladaptive remodelling.4
The gastrointestinal tract contains a dynamic microbial
community with a combined genome exceeding the human
genome by two orders of magnitude.5 It provides a large
and complex cache of potential triggers, enhancers, and in-
hibitors of inflammatory and metabolic pathways. The com-
position of the microbiota determines the type and number
of molecules that challenge the mucosal barrier and interact
with the immune system within the gut wall and systemically.
As an example, the gut microbial composition in patients with
inflammatory bowel disease differs from that of healthy con-
trol subjects, potentially contributing to intestinal inflamma-
tion. Vice versa, genetic susceptibility factors in patients
with inflammatory bowel disease may shape the microbial
community composition, potentially in a pro-inflammatory
direction.6 Notably, the gut microbiota seems to be of impor-
tance not only for intestinal inflammation but also for sys-
temic inflammatory and metabolic disorders like Type 2
diabetes7 and obesity.8 It may also play a role in atherosclero-
sis by interfering with inflammatory and metabolic pathways
that at least partly involve the metabolism of certain nutri-
ents containing carnitine (e.g. red meat) or phosphatidyl cho-
line (e.g. dairy products and egg).9 Hence, the gut microbiota
has been proposed as a cardio-metabolic target for
intervention.10
In patients with HF, the decreased cardiac output and con-
gestion contribute to ischaemia and oedema of the gut wall.
Consequently, structural and functional changes may cause
increased gut permeability or even secondary inflammation.
Sandek et al.11 reported a 210% increase in large intestine
permeability measured by sucralose excretion. The severity
of HF symptoms seems to correlate well with the magnitude
of permeability, the amount of pathogenic bacteria, and sec-
ondary inflammation.12
Several studies have shown that low-grade leakage of mi-
crobial products, such as lipopolysaccharide (LPS), occurs
across the gut wall.13,14 This may cause systemic inflamma-
tion by activating toll-like receptor 4 on cells of the innate im-
mune system,15 which again may promote gut leakage in the
gastrointestinal tract. Lipopolysaccharide-induced toll-like re-
ceptor 4 activation induces the release of inflammatory cyto-
kines like tumour necrosis factor, which could act as a
suppressor of cardiac function via several pathways, including
reduced mitochondrial activity, altered calcium homeostasis,
and impaired β-adrenergic signalling in cardiomyocytes.16
Other inflammatory cytokines, like interleukin (IL)-1 and
IL-6, may also promote myocardial dysfunction.16
We recently showed that the microbiota-dependent
marker trimethylamine N-oxide was associated with outcome
in patients with chronic HF.17 Other investigators have shown
that gut decontamination with antibiotics reduces intestinal
levels of LPS, monocyte expression of the LPS co-receptor
CD14, and the production of IL-6, IL-1β, and tumour necrosis
factor.18 Selective gut decontamination favourably affects
post-operative outcome in patients undergoing cardiac sur-
gery.19 Recently, our co-investigators in Brazil published a pilot
trial showing that manipulation of the gut microbiota could
promote LV functional improvement in patients with HF.20
Figure 1 shows some of the putative mechanisms involved in
the interaction between the cardiovascular system and the
gut. However, our knowledge of the interaction between the
gut microbiota, systemic inflammatory and metabolic distur-
bances, and myocardial function in patients with HF remains
limited, and other mechanisms than gut leakage could be in-
volved in the translation of a disturbed gut microbiota into ac-
tivation of systemic inflammatory and metabolic pathways.
Design
Study rationale and objectives
While most studies on inflammation in HF have focused on
downstream mediators of inflammation and tissue damage,
the present study will address the gut microbiota as a poten-
tial upstream trigger of inflammatory activation. In addition
to promoting inflammation, an altered gut microbiota may
play a key pathogenic role in HF through the induction of
metabolic disturbances.
We postulate that the gut microbiota is altered in patients
with HF and that the gut microbiota in these patients contrib-
utes to low-grade systemic inflammation as well as metabolic
disturbances. Furthermore, we assume that interventions
with probiotics or non-absorbable antibiotics will attenuate
these inflammatory and metabolic disturbances and
favourably affect cardiac function. We aim to investigate
whether treatment with the non-absorbable antibiotic
rifaximin or the probiotic yeast Saccharomyces boulardii
(ATCC 74012), on top of recommended treatment for HF, im-
proves LV ejection fraction (LVEF), quality of life, and exercise
capacity and reduces systemic inflammation in patients with
HF and reduced ejection fraction.
Outline
The GutHeart trial is a Phase II, randomized, open-label, con-
trolled trial conducted at three centres in Norway and one in
Brazil. The trial has been registered at ClinicalTrials.gov
(NCT02637167, www.clinicaltrials.gov).
Eligibility
The inclusion and exclusion criteria are presented in Table 1.
We include patients who have stable, symptomatic HF and
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who are not likely to improve further from recommended
treatment. Prior to enrolment, we require at least 3 months
optimal pharmacological treatment for HF and at least
6 months with cardiac resynchronization therapy, if indicated.
Exclusion criteria include concomitant diseases that we as-
sume affect the composition of the gut microbiota substan-
tially and antibiotic treatment within the last 3 months. We
also exclude patients who take probiotic drugs or over-the-
counter probiotic substances on a regular basis.
Procedures
Figure 2 is a flow chart depicting patient recruitment, ran-
domization, study drug allocation, and follow-up. We recruit
patients at the cardiology departments at four centres: Oslo
University Hospital, Rikshopitalet (Oslo, Norway), Oslo Uni-
versity Hospital, Ullevål (Oslo, Norway), Nordlandssykehuset
(Bodø, Norway), and Instituto Nacional de Cardiologia (Rio
de Janeiro, Brazil).
After verification of eligibility, the investigators obtain writ-
ten, informed consent from all participants. The patients then
undergo study-specific procedures, including clinical exami-
nation, echocardiography, a 6 min walk test, a quality of life
questionnaire (Minnesota Living with Heart Failure Question-
naire), and blood sampling for measuring safety and efficacy.
At inclusion, all participants are asked to complete a compre-
hensive food frequency questionnaire. They are asked to re-
frain from probiotics and probiotic foods during the study
period, except from small amounts of foods that are a part
of their usual diet, such as the occasional yoghurt. All drugs
taken by the patient, including over-the-counter drugs and
herbal medicines, are registered at inclusion and throughout
the study period. We measure the height and weight of all
study participants.
Randomization and allocation to treatment arm are per-
formed on the online platform Viedoc™ (PCG Solutions, Upp-
sala, Sweden). The randomization list was generated using
STATA 13™ (StatCorpLP, College Station, TX, USA). The patients
are assigned a unique patient identification number and are
randomized to one of three open-label treatment arms.
Faecal samples are provided at inclusion and after 3 and
6 months. We apply the Spinstool® preservation solution that
stabilizes DNA for 72 h at room temperature and register the
time from collection to freezer for all patients. After DNA ex-
traction, V3–V4 region of the 16S rRNA gene will be ampli-
fied. Libraries will be submitted to the Norwegian
Sequencing Centre (Oslo, Norway) for Illumina MiSeq se-
quencing (San Diego, CA, USA). The microbiota will be charac-
terized with regard to α-diversity and β-diversity and relative
abundance of individual taxa, with correction for multiple
comparisons.
Figure 1 Putative mechanisms involved in the interaction between the gut and the cardiovascular system. IL, interleukin; LPS, lipopolysaccharide;
TLR4, toll-like receptor 4; TMA, trimethylamine; TMAO, trimethylamine N-oxide; TNF, tumour necrosis factor.
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An extensive biobank will be established per accepted
common sampling and processing protocols at three study




The primary endpoint of this study is the baseline-adjusted
LVEF as measured by echocardiography after 3 months of in-
tervention. The trial is powered to detect a 5% point increase
in either intervention arm compared with the control group.
Secondary endpoints
The secondary endpoints will assess differences between ei-
ther of the treatment arms and the control group after
3 months’ intervention and after another 3 months’ follow-
up, regarding (i) the gut microbiota composition, (ii)
microbiota-related metabolites, (iii) parameters of cardiac
function other than LVEF, (iv) inflammatory and anti-
inflammatory mediators in plasma, serum, circulating
leucocytes, and peripheral blood mononuclear cells, (v)
health-related quality of life, (vi) functional capacity, (vii) en-
dothelial function measured by asymmetric dimethylarginine,
the L-arginine/asymmetric dimethylarginine ratio, and Endo-
PAT®, and (viii) safety. Endpoints are detailed in Table 2.
The trial is a proof-of-concept study regarding the effect of
altering the gut microbiota on cardiac function in patients
with HF. In addition to assessing differences between either
treatment arm and the control arm, we also plan to perform
secondary analyses as to whether altering the microbiota
through both treatments will affect the respective endpoints
(i.e. whether there is a difference in the baseline-adjusted
efficacy measures between the control arm and the two
treatment arms combined) and whether there are differ-
ences between the two treatment arms.
Statistical considerations
To observe a difference in LVEF of 5 percentage points be-
tween patients in either active drug arm compared with
controls, with an α of 5% and power of 80%, we will need
approximately 37 patients in each arm. The calculation is
based on a presumed standard deviation of LVEF of 7.5
percentage points. To increase the chance of attaining
significant differences in secondary endpoints and to allow
for dropout, we aim to include 50 patients in each arm.
No interim analysis is planned, unless there are a substan-
tially increased number of serious adverse events in either
of the intervention arms, as judged by the data monitoring
board.
The analyses will follow intention-to-treat principles. The
primary endpoint: baseline-adjusted LVEF at the end of
treatment (i.e. 3 months after start of treatment) will be
analysed by analysis of covariance, the statistical null hy-
pothesis being that LVEF does not differ between either
of the two treatment arms and the control arm. Secondary,
continuous efficacy variables will also be assessed by analy-
sis of covariance. If necessary, values will be log-
transformed to meet the assumptions of the test. Ordinal
categorical variables, such as New York Heart Association
functional class, will be analysed using ordinal logistic re-
gression, whereas count variables will be assessed by
Poisson regression. We intend to perform exploratory, sec-
ondary endpoint analyses according to the per-protocol
principle, where compliance above 80% throughout the
Table 1 Inclusion and exclusion criteria
Inclusion criteria
Between 18 and 75 years of age
Symptomatic heart failure, NYHA Class II–III
Left ventricular ejection fraction <40% on echocardiography
Receiving optimal treatment for heart failure for at least
3 months
Haemoglobin >100 g/L
Estimated glomerular filtration rate ≥30 mL/min
Alanine aminotransferase <150 U/L
Signed informed consent
Acceptable acoustic windows for echocardiographic assessment
Exclusion criteria
Treatment with antibiotics or probiotics within 12 weeks prior to
randomization
History of hypersensitivity to rifaximin or other rifamycin-derived
antimicrobial agents, or any of the components of Xifaxan®
History of hypersensitivity to S. boulardii, yeast, or any of the
components of Precosa®
Polypharmacy with increased risk for interactions, i.e. an
extensive list of medications (e.g. 10 drugs or more) that may
influence with the patient safety or compromise the study results
Malignancy of any cause, excluding basal cell carcinoma of the
skin, which has not been curatively treated >5 years ago, or
where there has been relapse within the last 5 years
Acute coronary syndrome within 12 weeks prior to
randomization
Impaired liver function classified as Child–Pugh B or C
Ongoing infection, including gastrointestinal infection
Inflammatory bowel disease
Bowel obstruction
Active myocarditis, including Chagas disease
Severe, primary valvular heart disease
Atrial fibrillation with ventricular rate >100/min
Initiation of cardiac resynchronization therapy within 6 months
prior to randomization
Any other, severe co-morbid disease that must be expected to
significantly reduce the efficacy of the interventional products,
survival, or compliance
Ongoing treatment with immunosuppressive drugs
Ongoing treatment with rifamycins other than rifaximin
Central venous catheter
Pregnancy or planned pregnancy
Nursing
Poor compliance
Any reason why, in the opinion of the investigator, the patient
should not participate
NYHA, New York Heart Association.
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treatment period will be regarded as protocol adherence.
Exploratory, secondary analyses will be made for efficacy
variables stratified by country (i.e. separate analyses for
Norwegian and Brazilian patients). Safety analyses will in-
clude tabulation of type and frequency of all adverse
events. Any serious adverse events will be reported with
comprehensive narratives.
Discussion
We have devised the GutHeart trial to assess an interplay
hitherto largely overlooked in medicine: the gut–heart axis
(Figure 1). Our assumption is that by manipulating the bacte-
rial composition of the gut content, we might be able to im-
prove the inflammatory and metabolic environment for the
cardiovascular system, thereby promoting cardiac healing
and adaptive remodelling. We have chosen to test this hy-
pothesis in a randomized controlled trial with the non-
absorbable antibiotic rifaximin, the probiotic yeast
S. boulardii, or no treatment (control) on top of recom-
mended treatment for HF. Saccharomyces boulardii was used
in the aforementioned pilot study conducted by our co-
investigators in Brazil, who found that treatment reduced
markers of inflammation and improved LVEF in patients with
HF. However, these results should be interpreted with cau-
tion because of the small sample size. We found it feasible
and scientifically important to investigate the same drug in
a larger and well-powered study.
Saccharomyces boulardii is a yeast, and the risk of
fungaemia must be recognized. In the clinical setting, this
probiotic is used in different long-term treatment regimens
such as in recurrent Clostridium difficile infections. The safety
data on S. boulardii are mostly derived from case reports.
Typical risk factors for fungaemia are the use of central ve-
nous catheters, enteral or parenteral nutrition, being treated
in an intensive care unit, and immunosuppression. In a meta-
analysis by Shen et al.21 investigating the use of probiotics in
C. difficile infections, 538 patients received S. boulardii. No
fungaemia was reported. To our knowledge, only limited data
exist on the use of S. boulardii in HF populations; thus, we
will remain vigilant in reporting adverse events.21 Rifaximin
was chosen for its local effects in the gut and its low absorp-
tion. It is a non-absorbable antibiotic with minimal systemic
effects. It has a broad microbial range and is indicated for
Figure 2 Study design. EF, ejection fraction; NYHA, New York Heart Association; QoL, quality of life.
982 C. C.K. Mayerhofer et al.
ESC Heart Failure 2018; 5: 978–985
DOI: 10.1002/ehf2.12332
treatment in a variety of clinical conditions such as travel-
lers’ diarrhoea, hepatic encephalopathy, and irritable bowel
disease with diarrhoea. Clostridium difficile infections have
been reported as a direct consequence of treatment with
rifaximin. This is an uncommon but potentially serious ad-
verse effect. Kimer et al.22 published a systemic review in
2014, including 19 RCTs and 1370 patients who were ran-
domized to rifaximin or placebo in the treatment of hepatic
encephalopathy. The length of treatment ranged from 5 to
180 days. None of the trials found a difference between
the rifaximin and the control groups regarding serious ad-
verse events. There were only two trials, comprising all to-
gether 203 patients, where treatment with rifaximin was
continued for >3 months with doses of 1.1 g or above. In
these groups, only two cases of C. difficile infections were
reported, suggesting an incidence rate of 0.1%. Given the
current state of knowledge, the large disease burden posed
by HF, and the favourable safety profile of the investiga-
tional drugs, we find that randomizing patients to different
treatments is justified. Gut microbiota manipulation remains
a promising, but far from proven, treatment option in pa-
tients with HF.
Our trial will be the first to produce solid evidence regard-
ing the effect of manipulating the gut microbiota in patients
with HF. Moreover, the observed association between gut mi-
crobiota and systemic inflammatory disorders does not nec-
essarily imply causality. Hence, proof-of-concept studies like
the GutHeart trial are needed to establish a causal
relationship.
Left ventricular ejection fraction is a strong predictor of all-
cause mortality and cardiovascular death,23 whereas an in-
crease is associated with a reduced risk of cardiac death.24
Left ventricular ejection fraction thus serves as a natural sur-
rogate endpoint in interventional studies in patients with sys-
tolic HF.25 Echocardiography is a readily available, safe, and
versatile imaging tool, which can be applied without concern
in patients with cardiac devices. When assessing LVEF, the
main limitation is image quality. To limit the impact of poor
acoustic settings, we demand that all eligible patients have
acceptable acoustic windows.
The study is powered to reveal a difference of 5 percent-
age point increase in either intervention group compared
with control. An inter-observer variability for LVEF assessed
by two-dimensional echocardiography of ±7% and a test–
retest reliability of ±5% has previously been reported.26,27
To minimize inter-observer differences, all images will be
analysed at the European Association of Cardiovascular
Imaging accredited echocardiography core lab at the Depart-
ment of Cardiology at Oslo University Hospital,
Rikshospitalet.
The study will expand our knowledge about the mecha-
nisms behind the inflammatory and dysregulated metabolic
states in chronic HF. We will assess biomarkers of microbial
translocation, a potential inducer of inflammation, and
markers of platelet and endothelial cell activation, potential
resultants of an inflammatory response. We will also perform
in-depth studies on metabolic disturbances consequence of
disturbed gut microbiota composition. In addition to measur-
ing circulating proteins and gene expression, we will perform
analyses in peripheral blood cells to evaluate regulatory
pathways.
Whereas focus has often been directed at the associa-
tion between the gut microbiota and systemic inflamma-
tion, less is known about the effects the gut microbiota
exerts on the regulation of metabolic pathways. An impor-
tant goal of the GutHeart trial will be to elucidate the gut–
heart metabolic axis. We hypothesize that interventions
targeting the gut microbiota will alter its composition to re-
duce microbiota-specific as well as systemic inflammation
and to exert favourable effects on metabolic pathways. In
turn, these changes may result in improved cardiac func-
tion as measured by echocardiography and also improve-
ment in functional capacity and quality of life. These
studies will give insight not only into how gut microbiota
interact with the systemic inflammatory and metabolic
pathways but also into how could it potentially delineate




• Baseline-adjusted LVEF as measured by echocardiography after
3 months of intervention
Secondary endpoints
• Gut microbiota composition
• Microbiota-related circulating metabolites including TMAO, plasma
lipidomics including primary and secondary bile acids, and plasma
metabolomics
• Left ventricular end-systolic and end-diastolic volumes, regional wall
motion score index as measured by echocardiography, New York
Heart Association functional classification, and neurohormones
(including NT-proBNP)













• Health-related quality of life as measured by the Minnesota Living
with Heart Failure Questionnaire
• Functional capacity (6 min walk test)
• Endothelial function assessed by Endo-PAT®
• Safety, including side effects and withdrawal
CRP, C-reactive protein; IL, interleukin; LPS, lipopolysaccharide;
LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal
pro-brain natriuretic peptide; TMAO, trimethylamine N-oxide;
TNF, tumour necrosis factor.
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Trial status
This study was initiated in March 2016 and is currently
recruiting patients. As of 19 September 2017, 75 patients have
been enrolled. We expect patient recruitment to be complete
by the third quarter of 2018. We expect the trial to be com-
pleted and results to be available in 2019. Demographic data
for the first 30 patients are presented in Table 3.
The baseline characteristics are comparable with those of
patients in recently published HF trials.28 A median N-terminal
pro-brain natriuretic peptide of 837.2 pg/mL (interquartile
range 334.1–1584.0) despite a mean LVEF of just 29 ± 5% tes-
tifies to the clinical stability of the patients and is consistent
with optimal evidenced-based treatment at baseline.
Ethical perspectives
The GutHeart trial is designed to assess the effect of a thera-
peutic intervention in a prevalent disease that imposes a
large burden on individual patients as well as society. The
trial is conducted according to Good Clinical Practice guide-
lines. Based on previous trials and drug pharmacodynamics,
we do not expect a substantial number of drug-related severe
adverse events. The trial complies with the Declaration of
Helsinki. The regional ethics committees as and the relevant
competent authorities have approved the trial. All patients
provide written informed consent before enrolment and
randomization.
Conclusions
The GutHeart trial is likely to lead to increased understanding
of the interactions between gut microbiota, inflammation,
metabolic disturbances, and cardiac function. Potentially,
our results will provide the rationale for new therapeutic
strategies in patients with HF. The findings could also be of
relevance for other disorders where there may be interac-
tions between gut microbiota on the one hand and inflamma-
tion and metabolic pathways on the other. Such disorders
include atherosclerosis and related metabolic disorders (e.g.
obesity, diabetes, and liver steatosis) as well as autoimmune
and autoinflammatory diseases.
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Table 3 Baseline characteristics of the first 30 patients
Age (years) ± SD 60 ± 7
Male gender—n (%) 25 (83)
Body mass index (kg/m2) 29 ± 6
Systolic blood pressure (mmHg) 118 ± 18
Diastolic blood pressure (mmHg) 75 ± 12
Heart rate (b.p.m.) 67 ± 11
Atrial fibrillation/flutter—n (%) 10 (33)
NYHA Class II/III—n (%) 21 (70)/9 (30)
Medical history
Smokers—n (%) 16 (53)
History of hypertension—n (%) 12 (40)








Haemoglobin (g/dL) 14.3 ± 1.3





Left ventricular ejection fraction (%) 29 ± 5
6 min walk test
Distance (m) 480 ± 157
Peak heart rate (b.p.m.) 96 ± 18
IQR, interquartile range; NYHA, New York Heart Association; SD,
standard deviation.
Data are given as n (%), mean ± SD, or median (IQR) as
appropriate.
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